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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground/Purpose: Silver nanoparticles are receiving increasing attention in biomedical ap-
plications. This study aims at evaluating the antifungal properties of silver nanoparticles
against the pathogenic fungus Trichosporon asahii.
Methods: The growth of T. asahii on potato dextrose agar medium containing different con-
centrations of silver nanoparticles was examined and the antifungal effect was evaluated using
minimum inhibitory concentration. Scanning and transmission electron microscopy were also
used to investigate the antifungal effect of silver nanoparticles on T. asahii.
Results: Silver nanoparticles had a significant inhibitory effect on the growth of T. asahii. The
minimum inhibitory concentration of silver nanoparticles against T. asahii was 0.5 mg/mL,
which was lower than amphotericin B, 5-flucytosine, caspofungin, terbinafine, fluconazole,
and itraconazole and higher than voriconazole. Silver nanoparticles obviously damaged the cell
wall, cell membrane, mitochondria, chromatin, and ribosome.
Conclusion: Our results demonstrate that silver nanoparticles have good antifungal activity
against T. asahii. Based on our electron microscopy observations, silver nanoparticles may
inhibit the growth of T. asahii by permeating the fungal cell and damaging the cell wall and
cellular components.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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Nanotechnology is an emerging scientific field considered to
have potential to generate new and innovative materials.
Nanotechnology provides the ability to open new avenues
to prevent and treat diseases by tailoring materials on an
atomic scale.1,2 Nanomaterials may provide solutions to
technological and environmental challenges in the areas of
solar energy conversion, catalysis, medicine, and water
treatment.3,4 Due to their unique properties, silver nano-
particles are receiving increasing attention in biomedical
applications such as biological sensing, antimicrobial oint-
ments, medical diagnostics, cancer therapy, drug delivery,
and artificial implants.5e7
Antimicrobial characteristics of silver ions and silver-
based compounds have been reported for a variety of ap-
plications. Many studies have shown that silver nano-
particles are highly stable and toxic to bacteria, fungus,
and viruses such as Escherichia coli, Staphylococcus aureus,
Bacillus subtilis, Klebsiella mobilis, Mycobacterium tuber-
culosis, Candida albicans, hepatitis B, human immunodefi-
ciency virus-1, and syncytial virus.8e12 Carbon nanoscrolls
AgNPs and graphene oxide AgNPs exhibit enhanced anti-
fungal activities.13 Silver nanoparticles in combination with
nystatin and chlorhexidine digluconate could enhance
antifungal activity against Candida albicans and Candida
glabrata.14 The release of silver ions from the crystalline
core of silver nanoparticles contributes to the antimicrobial
activity of these nanomaterials, making them useful for
many applications in antimicrobial treatment.5,15
Trichosporon asahii is an emerging fungal pathogen and
has several growth forms: yeast-like round or oval spores,
germtubes, or pseudohyphae in response to environmental
cues.16 In recent years, there have been even more reports
about infection and drug resistance of T. asahii,17,18 which
can invade the human body through implantable catheters,
abraded skin, mucosa, or the respiratory tract, causing
systematic and fatal trichosporosis.19,20 Trichosporon in-
fections are associated with a wide spectrum of clinical
manifestations, ranging from superficial cutaneous involve-
ment in immunocompetent individuals to severe systemic
diseases in immunocompromised patients. Due to limited
availability of antifungal drugs, it is difficult to prevent and
treat T. asahii infection. There is a strong incentive to
develop new and more effective antifungal agents.
Although silver nanoparticles have shown great potential
in biomedical applications, little is known about their
antifungal effect on T. asahii, or their mechanism of action.
Using a minimum inhibitory concentration (MIC) assay and
electron microscopy (EM), we investigated the effect of
silver nanoparticles on T. asahii. Our study provides a basis
for using silver nanoparticles for potential prevention and
treatment of T. asahii infections.
Materials and methods
Materials
A clinical strain (CBS2479) and several environmental
strains (CBS8904, CBS7137, and CBS8520) of T. asahii were
purchased from Centraalbureau voor Schimmelcultures(Utrecht, The Netherlands). Further clinical strains (BZ701,
BZ702, BZ703, BZ704, BZ705, BZ705R, BZ901, BZ902, BZ121,
BZ122, BZ123, BZ124, and BZ125) were isolated from pa-
tients at General Hospital of Beijing Military Command
(Beijing, China) that were infected by T. asahii. Potato
dextrose agar (PDA) medium was used to grow and maintain
the T. asahii cultures. A solution of silver nanoparticles
(1000 ppm) was purchased from Huzheng Nano Technology
Co., Ltd (Shanghai, China). Amphotericin B and terbinafine
were purchased from SigmaeAldrich (St Louis, MO, USA).
Fluconazole and 5-flucytosine were purchased from Wako
Chemicals (Richmond, VA, USA). Caspofungin was pur-
chased from Merck Pharmaceutical Co., Ltd (Whitehouse
Station, NJ, USA). Itraconazole was purchased from
XianeJanssen Pharmaceutical Ltd (Xi’an, China) and vor-
iconazole was from Pfizer, Inc. (Hong Kong, China). Scan-
ning EM (SEM) and transmission EM (TEM) images were
obtained using a Hitachi H-TM3000 scanning electron mi-
croscope (Tokyo, Japan) and a Hitachi H-7650 transmission
electron microscope (Tokyo, Japan), respectively.
Antifungal test
To examine the antifungal effect of silver nanoparticles,
T. asahii cells were grown in PDA liquid medium at 35C for
2 days, and then 1  106 colony-forming units/mL cells
were plated on fresh PDA solid media containing different
concentrations of silver nanoparticles (1 mg/mL, 2 mg/mL,
4 mg/mL, 6 mg/mL, 8 mg/mL, 16 mg/mL, and 32 mg/mL) and
incubated at 35C for 5 days. Silver-free PDA plates,
cultured under the same conditions, were used as controls.
The sizes of the colonies were measured.
EM observation
The size and morphology of the bacteria were examined by
SEM. Prior to SEM analysis, untreated and treated (4 mg/mL
of silver nanoparticles) fungal cells were deposited on a
Millipore filter and processed as previously described.21 In
addition, TEM was used to examine the ultrastructure of
the treated fungal cells, using standard procedures.22
Measurement of MIC
The MIC of the antimicrobial activity of silver nanoparticles
was evaluated according to the National Committee for
Clinical Laboratory Standards.23 The antimicrobial effec-
tiveness was determined against the final microorganism
concentration of 106 colony-forming units/mL. Fungal
growth was completely inhibited under the MIC. Ampho-
tericin B (AMB), 5-flucytosine, caspofungin, terbinafine,
fluconazole (FLC), itraconazole, and voriconazole were
used as controls. All analyses were carried out in triplicate.
Results
Examination of the silver nanoparticles
The silver nanoparticles were examined using TEM (Fig. 1).
Silver nanoparticles were round and had diameters of
5e20 nm.
Figure 1. Transmission electron microscopy micrograph of
the silver nanoparticles (1000 ppm, Huzheng Nano Technology
Co., Ltd).
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asahii
Compared to the control group (no silver nanoparticles),
the growth of T. asahii was obviously inhibited by the silver
nanoparticles in a concentration-dependent manner. The
size of the colonies decreased with the increasing concen-
tration of silver nanoparticles (Fig. 2). When the concen-
tration of silver nanoparticles was >8 mg/mL, no colony
growth was observed on the plates. When the concentra-
tion was <2 mg/mL, the silver nanoparticles showed no
inhibitory effect on colony growth (data not shown).MICs of silver nanoparticles and other drugs against
T. asahii
MICs of silver nanoparticles and other drugs against T.
asahii are shown in Table 1. The MIC of silver nanoparticles
were estimated to be 0.5e1 mg/mL, which were lower than
those of AMB, 5-flucytosine, caspofungin, terbinafine, FLC,
and itraconazole, but higher than voriconazole. There was
no significant difference in MIC values of silver nano-
particles between clinical strains and environmental
strains.Figure 2. Trichosporon asahii (clinical strain CBS2479) grown on
silver nanoparticles. The concentration of silver nanoparticles from
8 mg/mL.Effects of silver nanoparticles on the surface
morphology of T. asahii
SEM was used to evaluate the surface morphology of
T. asahii. In the absence of silver nanoparticles, hyphae of
T. asahii grew vigorously and had an average diameter of
3 mm; the cell wall was intact (Fig. 3A). When treated with
4 mg/mL silver nanoparticles, the mycelium obviously
deformed, distorted, shrunk, and fractured, and the sur-
face of mycelium was damaged leading to the outflow of
intracellular components and shrinkage of mycelium
(Fig. 3B). The damage was more serious at higher concen-
trations of silver nanoparticles.
Effects of silver nanoparticles on the ultrastructure
of T. asahii
TEM was used to evaluate the ultrastructure of both the
control and silver nanoparticle (4 mg/mL) treated T. asahii
cells. The cell structure of the untreated cell was intact
(Fig. 4A). When treated with silver nanoparticles, cell wall
and cell membrane structure was severely damaged
(Fig. 4BeF). Dead cells were often observed, as suggested
by the disappearance of the cell wall and cell membrane
(Fig. 4G). Serious damage and degeneration of organelles
was observed in silver-treated cells, including condensation
and margination of chromatin, depolymerization of ribo-
somes, thinning of matrix, and fragmentation of mito-
chondria (Fig. 4H). Multivesicular bodies (Fig. 4I) and
myeloid bodies (Fig. 4J), resulting from degeneration of
organelles, were observed. The organelles were degraded,
leading to empty space inside the cell (Fig. 4E). Silver
nanoparticles were seen inside the cells (Fig. 4H and J) and
on cell walls (Fig. 4K).
Discussion
The antimicrobial effects of silver have been known for
many years. Over the past several years, the use of silver or
silver salts as key components to control microbial prolif-
eration has become increasingly popular.24 As a broad-
spectrum antimicrobial agent, silver nanoparticles are
widely used in medical and consumer products, including
household antiseptic sprays and antimicrobial coatings for
medical devices.25
In this study, we demonstrated that the growth of
the pathogenic fungus T. asahii was inhibited by silverpotato dextrose agar plates with different concentrations of
left to right was 0 mg/mL, 2 mg/mL, 4 mg/mL, 6 mg/mL, and
Table 1 Minimum inhibitory concentration (MIC) of silver nanoparticles and other common antifungal drugs against Tricho-
sporon asahii
Strains MIC (mg/mL)
NAG AMB 5FC CAS TBF FLC ITC VRC
CBS2479 0.50  0.00 5.33  2.31 26.67  9.24 32.00  0.00 8.00  0.00 1.67  0.58 0.83  0.29 0.06  0.00
BZ701 0.67  0.29 13.33  4.62 16.00  0.00 21.33  9.24 10.67  4.62 1.67  0.58 1.00  0.00 0.05  0.02
BZ702 0.50  0.00 13.33  4.62 21.33  9.24 16.00  0.00 10.67  4.62 1.00  0.00 1.33  0.58 0.04  0.02
BZ703 1.00  0.00 13.33  4.62 16.00  0.00 21.33  9.24 10.67  4.62 1.33  0.58 0.83  0.29 0.03  0.00
BZ704 0.67  0.29 13.33  4.62 21.33  9.24 16.00  0.00 10.67  4.62 1.00  0.00 1.67  0.58 0.06  0.00
BZ705 0.50  0.00 13.33  4.62 16.00  0.00 21.33  9.24 8.00  0.00 1.67  0.58 1.00  0.00 0.04  0.02
BZ705 R 0.50  0.00 1.67  0.58 26.67  9.24 16.00  0.00 16.00  0.00 13.33  4.62 0.67  0.29 0.06  0.00
BZ901 0.67  0.29 16.0  0.00 32.00  0.00 26.67  9.24 13.33  4.62 2.00  0.00 1.67  0.58 0.10  0.03
BZ902 1.00  0.00 13.33  4.62 21.33  9.24 21.33  9.24 6.67  2.31 1.67  0.58 1.00  0.00 0.08  0.03
BZ121 0.83  0.29 8.0  0.00 32.00  0.00 53.33  18.48 8.00  0.00 2.00  0.00 1.67  0.58 0.10  0.03
BZ122 0.67  0.29 13.33  4.62 26.67  9.24 32.00  0.00 4.00  0.00 1.67  0.58 1.67  0.58 0.12  0.00
BZ123 0.5  0.00 10.67  4.62 16.00  0.00 42.67  18.48 6.67  2.31 1.00  0.00 1.00  0.00 0.06  0.00
BZ124 0.67  0.29 10.67  4.62 26.67  9.24 53.33  18.48 5.33  2.31 0.67  0.29 0.67  0.29 0.08  0.03
BZ125 0.83  0.29 21.33  9.42 21.33  9.24 32.00  0.00 6.67  2.31 1.33  0.58 1.00  0.00 0.10  0.03
CBS8904 0.5  0.00 26.67  9.42 16.00  0.00 21.33  9.24 4.00  0.00 0.67  0.29 0.25  0.00 0.03  0.00
CBS7137 0.67  0.29 32.00  0.00 21.33  9.24 10.67  4.62 4.00  0.00 1.67  0.58 0.33  0.14 0.04  0.02
CBS8520 0.67  0.29 32.00  0.00 26.67  9.24 10.67  4.62 5.33  2.31 1.00  0.00 0.42  0.14 0.04  0.02
Data are presented as mean  standard deviation.
5FCZ 5-flucytosine; AMBZ amphotericin B; CASZ caspofungin; FLCZ fluconazole; ITCZ itraconazole; NAGZ silver nanoparticles;
TBF Z terbinafine; VRC Z voriconazole.
Antifungal effect of silver nanoparticles 185nanoparticles (Fig. 2). Similarly, a recent publication also
showed that silver nanoparticles had antimicrobial effects
against both Lactobacillus casei and T. asahii isolated from
spoiled milk.26 Our electron microscopy analysis showed
that that silver nanoparticles damaged the cell wall and
cell membrane, penetrated inside the cells, damaged the
organelles including mitochondria and ribosome, and
caused condensation and margination of chromatin, a
marker of apoptotic cell death. Moreover, due to their
small size, the silver nanoparticles may attach to the cell
surface and get into the cells directly without damaging the
cell wall and then cause the death of the cell. In a previous
report on the bactericidal activity of silver nanoparticles, it
was shown that disruption of membranes of E. coli by silver
nanoparticles significantly increases its permeability,
leading to abnormal transport through the plasma mem-
brane and, finally, cell death.27 Similar studies have also
been reported in other fungal species, and mostly focusedFigure 3. Scanning electron microscopy micrographs of (A) un
T. asahii treated with a suspension of silver nanoparticles in potaton the pathogenic fungus Candida albicans.9 To the best of
our knowledge, this is the first report about inhibition of
T. asahii by silver nanoparticles.
Several studies have reported that the electrostatic
attraction between the negatively charged cell membrane
of microorganisms, including bacteria, viruses, and fungi,
and the positively charged nanoparticles is crucial for the
antibacterial mode of these particles.28 It was believed that
silver nanoparticles with large surface areas can easily form
Agþ, binding to functional groups (-SH) of proteins and
resulting in protein denaturation.29,30 Silver nanoparticles
might also lead to protein denaturation and proton pump
destruction by binding to the surface proteins of fungi,
increasing the permeability of the membrane or protein
lipid bilayer, finally resulting in disruption of the cell
membrane.31 According to previous studies,2,32 it is likely
that silver nanoparticles damage the transport system,
causing efflux of intracellular ions and accumulation oftreated Trichosporon asahii (clinical strain CBS2479) and (B)
o dextrose medium (4 mg/mL) for 5 days.
Figure 4. Transmission electron microscopy images showing the effects of silver nanoparticles on the ultrastructure of Tri-
chosporon asahii. (A) The integral cellular structure can be seen in an untreated cell. (BeK) T. asahii was treated with 4 mg/mL of
silver nanoparticles. (B) The cell wall was vague, (C) fell off, and (D) ruptured; (E) the cell membrane shrunk and the organelles
were degraded, leading to the empty space inside the cell; and (F) rupture and dissolution. Red arrows (in BeD, and F) indicate the
damage to cellular structure. (G) The cell wall and cell membrane disappeared, and only organelles could be seen within the cell.
(H) Serious damage and degeneration of organelles was observed in silver-treated cells; (I) multivesicular bodies; and (J) myelin
body. Silver nanoparticles can be seen both inside the cells (H and J, red arrows) and on cell walls (K, red arrow).
186 Z.-K. Xia et al.silver ions, and blocking processes such as metabolism and
respiration. Moreover, it is speculated that the bacterial
cells in contact with silver nanoparticles may take up silver
ions, which could facilitate the generation of reactive ox-
ygen species and consequently cause cell death.33 Silver
nanoparticles may also cause DNA damage and damage
replication ability.2
In this study, we also found that an environmental strain
was more sensitive to commonly used antifungal drugs(except AMB) than were clinical strains, possibly because
the clinical strains have been exposed to certain antifungal
drugs and therefore were resistant. This notion is further
supported by the fact that the strain isolated from the
patient treated with FLC and other drugs (BZ705R) was
more resistant to drugs than the strain isolated from the
same patient prior to drug treatment (BZ705). BZ705R has a
higher MIC for FLC, further suggesting that exposure to
certain medicine causes less drug susceptibility and
Antifungal effect of silver nanoparticles 187tolerance. However, the sensitivity of environmental and
clinical strains to the silver nanoparticles was similar, and
silver nanoparticles could inhibit the T. asahii growth more
efficiently than the other six antifungal drugs, which are
used widely in clinical practice. These results suggest that
silver nanoparticles have good sterilization effect on both
clinical strains and environmental strains. Thus, silver
nanoparticles can be used as a potential antifungal agent
for T. asahii. One concern is the possible cytotoxicity of
silver nanoparticles to humans.34,35 A number of studies
have shown that silver nanoparticles have no cytotoxicity to
human cells at low concentrations, but that increased doses
might be cytotoxic.35e37
In conclusion, we have demonstrated that silver nano-
particles exhibit excellent antifungal activity against T.
asahii. However, the toxicity of silver nanoparticles to
humans needs to be further evaluated in order to make
them applicable to diverse medical devices and antimi-
crobial systems.
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